Unlocking maternal trial data

⚡ The Signal

Historically, pregnant and lactating patients have been systematically excluded from clinical trials due to liability concerns, leaving a massive gap in real-world medical data. As regulators demand structured post-marketing evidence, biopharma giants face severe data fragmentation when trying to evaluate drug safety in these demographics. The friction is reaching a tipping point as industry leaders push for structured updates, such as adding a dedicated ClinicalTrials.gov pregnant and lactating patients checkbox to track studies more effectively.

🚧 The Problem

When therapeutics are prescribed during pregnancy, critical safety and efficacy outcomes remain buried inside unstructured clinician notes, unstructured electronic health record (EHR) fields, and fragmented hospital databases.

Generalist real-world data brokers rely heavily on standardized insurance claims, which completely fail to capture granular maternal health variables like gestational timing, trimester-specific exposures, or post-partum outcomes. When biopharma firms need to submit regulatory post-marketing commitment reports to the FDA or EMA, they are forced to rely on slow, manual record abstractions that cost millions of dollars and take months to execute.

🚀 The Solution

Enter Materis. Materis is an automated real-world evidence extraction platform built specifically to bridge the maternal health data gap.

By plugging directly into health system data warehouses and clinical trial management systems, Materis ingests unstructured clinical notes, extracts key maternal entity markers, and normalizes timelines across pregnancy and lactation periods. The platform converts disparate clinical observations into hyper-structured, FDA- and EMA-compliant real-world evidence datasets ready for biopharma regulatory filings.

🎧 Audio Edition

Listen to Ada and Charles discuss today's business idea.

If you're reading this in your email, you may need to open the post in a browser to see the audio player.

💰 The Business Case

Revenue Model

Materis drives revenue across three high-margin streams:

• Annual Data Subscriptions: Tiered recurring access to structured maternal real-world evidence datasets organized by therapeutic class for biopharma regulatory and safety teams.
• Per-Cohort Extraction API Fees: Usage-based pricing for clinical research organizations querying clinical databases and active EHR pipelines.
• Regulatory Submission Package Fees: Fixed-fee, high-value evidence reports formatted specifically for FDA and EMA post-marketing commitment filings.

Go-To-Market

Materis scales its network through a developer-first and institutional co-op motion:

• Open-Source De-identification CLI: Launch a free Python command-line utility (maternal-deid) for clinical researchers to anonymize unstructured pregnancy notes, acquiring developer leads inside key health systems.
• Pregnancy Safety Index: A public programmatic directory mapping all FDA-approved therapeutics against their documented pregnancy data gaps, driving high-intent organic search traffic from regulatory affairs executives.
• Academic CRO Co-Op: Partner with top academic medical centers to structure their legacy maternal health records at no cost in exchange for dataset commercialization rights to biopharma partners.

⚔️ The Moat

Legacy platforms like TriNetX, Aetion, and Komodo Health focus on general claims and high-level medical records, lacking specialized clinical entity models for maternal care.

Materis embeds directly into health system clinical workflows via FHIR and HL7 proxies, accumulating proprietary, longitudinal maternal data schemas. Once integrated, the combination of workflow lock-in and accumulating longitudinal RWE creates prohibitive switching costs for health systems and pharma regulatory teams alike.

⏳ Why Now

Regulators are placing stricter demands on post-market drug safety monitoring, highlighting the urgent need for dedicated evidence tracking like the proposed pregnancy and lactation registry updates.

At the same time, capital is flooding into computational medicine, with the AI drug discovery market projected to reach $13.8 billion by 2033. To power these models, biopharma requires specialized, structured real-world data. Meanwhile, health systems are rapidly upgrading their data pipelines as part of a broader transformation in building the future of healthcare revenue and data management.

🛠️ Builder's Corner

Building an automated pipeline like Materis requires an architecture optimized for clinical NLP and strict data compliance.

A natural technical stack reaches for a FastAPI backend in Python, utilizing NLP libraries such as SpaCy and Med7 for specialized clinical entity recognition and tokenization of doctor notes. Data ingestion can be handled through FHIR and HL7 interfaces, sending raw text through automated de-identification logic aligned with Safe Harbor standards before validating payloads using Pydantic schemas.

For storing and querying these records, PostgreSQL extended with pgvector enables semantic cohort searching across longitudinal patient histories. The backend then orchestrates automated workflows to export datasets directly into compliant electronic Common Technical Document (eCTD) formats for seamless submission to regulatory agencies.

Legal Disclaimer: GammaVibe is provided for inspiration only. The ideas and names suggested have not been vetted for viability, legality, or intellectual property infringement (including patents and trademarks). This is not financial or legal advice. Always perform your own due diligence and clearance searches before executing on any concept.